Crossbow Therapeutics: $1.8B valuation, IPO Readiness 48, series_e. Biotech company developing precision antibody therapies for cancer treatment. Track live on The IPO Stack.
Biotech company developing precision antibody therapies for cancer treatment
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Crossbow Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Crossbow Therapeutics has not announced a specific IPO date as of 2026. Track TechStackIPO for the latest funding milestones and IPO signals. Subscribe to The IPO Stack newsletter for weekly updates.
Crossbow Therapeutics is valued at $1.8B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Crossbow Therapeutics shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Crossbow Therapeutics scores 48/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Crossbow Therapeutics has raised $450M in total venture capital and private equity funding, with backing from Taiho Ventures, Arkin Bio Ventures.
Crossbow Therapeutics's notable investors include Taiho Ventures, Arkin Bio Ventures. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Crossbow Therapeutics is a Biotech / Oncology company. Biotech company developing precision antibody therapies for cancer treatment.